Lei H, Chao L, Miao T, et al. - By performing a retrospective analysis of data on pediatric patients who received intranasal dexmedetomidine sedation for non-invasive investigations at the Kunming Children's Hospital between October 2017 and August 2018, researchers determined the incidence of bradycardia in children receiving intranasal dexmedetomidine sedation as well as explored the related risk factors. A total of 9,984 children qualified for entry, of those, bradycardia developed in 228 cases (2.3%). In children, the overall incidence of bradycardia following sole use of intranasal dexmedetomidine sedation was estimated to be 2.3%. A 1.48-fold higher risk of bradycardia was observed in male children. However, blood pressure was within the normal range in children who developed bradycardia. An effective strategy to treat bradycardia induced by intranasal dexmedetomidine sedation is simple wake-up.